Tag: trial-patients

(Reuters) – Gradually increasing the dose of Biogen Inc’s experimental Alzheimer’s disease drug appeared to reduce the risk of brain swelling compared to higher fixed doses, interim 12-month results from a small study released on Thursday showed. “These data appear solid to us, and if anything provide additional confidence in the program and viability of…